EpiVax nets NIH grant for flu vaccine
EpiVax Inc., a Providence, R.I.-based developer of therapeutics for cancer and autoimmune diseases, has attracted a $458,000 grant from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health. The grant will be used by the company to develop a universal influenza vaccine.
EpiVax’s influenza vaccine is designed to identify and evaluate T cell epitopes, which can prompt an immune response to protect the body. In addition to a universal influenza vaccine, the company is developing similar vaccines for poxviruses, tularemia, TB, H. pylori, and HIV.